Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-08-21
2007-08-21
Navarro, Mark (Department: 1645)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S015000, C424S234100
Reexamination Certificate
active
10799016
ABSTRACT:
The structure and specificity of a recombinant α2,3-sialyltransferase fromCampylobacterspp., is disclosed. Also provided are methods for using the α2,3-sialyltransferase in the production of desired carbohydrate structures and nucleic acids that encode the sialyltransferase.
REFERENCES:
patent: 5352670 (1994-10-01), Venot et al.
patent: 5374541 (1994-12-01), Wong et al.
patent: 5494790 (1996-02-01), Sasaki et al.
patent: 5545553 (1996-08-01), Gotschlich
patent: 5691138 (1997-11-01), Guesdon et al.
patent: 5998138 (1999-12-01), Stonnet et al.
patent: 6096529 (2000-08-01), Gilbert et al.
patent: 6210933 (2001-04-01), Gilbert et al.
patent: 6399336 (2002-06-01), Paulson et al.
patent: 6503744 (2003-01-01), Gilbert et al.
patent: 6699705 (2004-03-01), Gilbert et al.
patent: 6709834 (2004-03-01), Gilbert et al.
patent: 6723545 (2004-04-01), Gilbert et al.
patent: 6905867 (2005-06-01), Gilbert et al.
patent: 6911337 (2005-06-01), Gilbert et al.
patent: 7026147 (2006-04-01), Gilbert et al.
patent: 7192756 (2007-03-01), Gilbert et al.
patent: 2004/0229313 (2004-11-01), Gilbert et al.
patent: 173149 (1986-03-01), None
patent: WO96/32491 (1996-10-01), None
patent: WO97/47749 (1997-12-01), None
patent: WO98/31826 (1998-07-01), None
Gilbert et al, 1996, Journal of Biological Chemistry (refernce of record), vol. 271 (45), p. 28271-28276.
Gilbert, Michel et al, The Journal of Biological Chemistry, vol. 271(45), Nov. 8, 1996, pp. 28271-28276.
Moran, AP et al, Journal of endotoxin research, vol. 3(6), Dec. 1996, pp. 521-531.
Bowie et al.Science257:1306-1310 (1990).
Burgess et al.J. Cell Bio.111:2129-2138 (1990).
Lazar et al.Mol. Cell. Biol8:1247-1252 (1988).
Yamashiro et al.Glycoconjugate J.12:894-900 (1995).
Yuki et al.J. Neurological Sciences130:112-116 (1995).
Aoki et al., “Analysis of the substrate binding sites of human galactosyltransferase by protein engineering,”EMBO J.9:3171-3178 (1990).
Aspinall et al., “Lipopolysaccharides of Campylobacter jejuni Serotype 0:19: Structures of Core Oligosaccharide Regions from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barre Sundrome,”Biochemistry33: 241-249 (1994).
Apsinall, et al. “Lipopolysaccharides ofCampylobacter jejuniSerotype O:19: Structures of 0 Antigen Chains from the Serostrain and Two Bacterial Isolates from Patients with the Guillain-Barre Syndrome,”Biochemistry33: 250-255 (1994).
Bradbury, et al.J. of Clinical Microbiol.,(Sep. 1985) vol. 22(3), pp. 339-346, (abstract only).
Chang, et al.Glycobiology,(May 1995) vol. 5(3), pp. 319-325.
Frosch et al., “Evidence for a common molecular origin of the capsule gene loci in Gram-negative bacteria expressing group II capsular polysaccharides,”Mol. Microbiol.5: 1251-1263 (1991).
Gilbert et al., “Cloning of the Lipooligosaccharide a-2-3-Sialyltransferase from the Bacterial PathogensNeisseria meningitidisandNeisseria gonorrhoeae,” J. Biol. Chem.,271:28271-28276 (1996).
Gilbert et al., “Characterization of a recombinant Neisseria meningitidis a-2,3-sialyltransferase and its acceptor specificity ,”Eur. J. Biochem.249: 187-194 (1997).
Gilbert, et al. “The Synthesis of Sialylated Oligosaccarides Using a CMP-Neu5Ac Synthetase/sialyltransferase Fusion”Nature Biotechnology(Aug. 1998) vol. 16, pp. 769-772.
Gillam and Smith, “Site-Specific Mutagenesis Using Synthetic Oligodeoxyribonucleotide Primers: I. Optimum Conditions and Minimum Oligodeoxyribo-Nucleotide Length,”Gene8:81-97 (1979).
Guo, et al.Applied Biochemistry and Biotechnology,Oct.-Nov. 1997, vol. 68 (1-2), pp. 1-20.
Imai, et al.Cytobios,(1994) vol. 78(313), pp. 115-122 (abstract only).
Ito et al.,Pure Appl. Chem. ,“Synthesis of Bioactive sialosides,”65:753 (1993).
Jamieson, et al.Comparative Biochemistry and Physiology,(1993) vol. 105(1), pp. 29-33.
Kajihara et al., “A Novel a-2,6-Sialyltransferase: Transfer of Sialic Acid to Fucosyl and Sialyl Trisaccharides,”J. Org. Chem.61: 8632-8635.
Kleene et al., “Expression of Soluble Active Human B1, 4 Galactosyltransferase inSaccharomyces Cerevisiae,” Biochem. Biophys. Res. Commun.201:160-167 (1994).
Klohs, et al.Cancer Res.,(1979) vol. 39(4), pp. 1231-1238.
Korolik, et al.Microbiology,(Nov. 1997) vol. 143(pt11), pp. 3481-3489.
Kuroki et al., “Campylobacter jejuniStrains from Patients with Guillain-Barre Syndrome Belong Mostly to Penner Serogroup 19 and Contain B-N-Acetylglucosamine Residues,”Ann Neurol33:243-247. (1993).
Mandrell, et al.Immunobiology,(1993) vol. 187(3-5), pp. 382-402.
Maskell, et al.Mol. Microbiol. ,(1991) vol. 5(5), pp. 1013-1022, (abstract only).
Moran et al., “Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease,”MS Immunol. Med. Microbiol.16:105-115 (1996).
Moran et al., “Molecular mimicry of host structures by lipopolysaccharides ofCampylobacterandHelicobacterspp: implications in pathogenesis,”J. Endotoxin Res.3:521-531.
Nishiu et al., “Characterization of Rat N-Acetylglucosaminyltransferase I Expressed inEsherichia coli,” Biosci. Biotech. Biochem.59 (9):1750-1752 (1995).
Parsons, et al.Microbial Pathogenesis,(1993) vol. 14(4), pp. 329-335.
Preston et al., “The Lipooligosaccharides of Pathogenic Gram-Negative Bacteria,”Crit. Rev. Microbiol.22:139-180.
Rest, et al.Microbial Pathogenesis,(1995) vol. 19(6), pp. 379-390.
Reuter et al., “Sialic Acids Structure—Analysis—Metabolism—Occurrence—Recognition,”Biol. Chem.Hoppe-Seyler 377:325-342.
Roberts et al., Generation of an antibody with enhancedNature328:731-734 (1987).
Ropper, “The Guillain-Barre Syndrome,”N. Engl. J. Med.326: 1130-1136.
Salloway, et al.Infection Immunity,(Aug. 1996) vol. 64(8), pp. 2945-2949.
Smith, et al.Microbial Pathogenesis,(1995) vol. 19(6), pp. 365-377.
Steenbergen, et al.Journal of Biochemistry,(Feb. 1998) vol. 174(4), pp. 1099-1108.
Skirrow,Brit. Med. J. “Campylobacterenteritis: a ‘new’ disease,” 2:9-11 (1977).
Taylor, et al.Antimicrobial Agents&Chemotherapy(Dec. 1983), vol. 24(6), pp. 930-935, (abstract only).
Taylor, et al.Antimicrobial Agents and Chemotherapy,(May 1981) vol. 19(5), pp. 831-835 (abstract only).
Varki, “Biological Roles of Oligosaccharides: all of the theories are correct,”Glycobiology3:97-130.
Vogel, et al.Medical Microbiology and Immunology,(Oct. 1997) vol. 186(2-3), pp. 159-166.
Weiser, et al.Critical Reviews in Clinical Laboratory Sciences,(Jun. 1981) vol. 14(3), pp. 189-239.
Weisgerber et al., “Complete nucleotide and deduced protein sequence of CMP-neuAc: poly-a-2,8 sialosyl sialyltransferase ofEscherichia coliK1,”Glycobiol.1:357-365 (1991).
Williams et al., “Large-scale expression of recombinant sialyltransferases and comparison of their kinetic properties with native enzymes,”Glycoconjugate J.12: 755-761.
Wakarchuk et al., “Mutational and crystallographic analyses of the active site residues of the Bacilluscirculans xylanase,” Protein Sci.3:467-475.
Yamamoto et al., “Purification and Characterization of a Marine Bacterial B-Galactoside a2,6-Sialyltransferase from Photobacterium damsela JT0160,”J. Biochem.120:104-110 (1996).
Yamamoto, et al.J. of Biochemistry,(Jan. 1998) vol. 123(1), pp. 94-100.
Yamashiro, et al.Glycoconjugate Journal,(Dec. 1995) vol. 12(6), pp. 894-900.
Gilbert Michel
Wakarchuk Warren W.
National Research Council of Canada
Navarro Mark
Portner Ginny Allen
Townsend and Townsend / and Crew LLP
LandOfFree
Lipopolysaccharide α-2,3 sialyltransferase of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipopolysaccharide α-2,3 sialyltransferase of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipopolysaccharide α-2,3 sialyltransferase of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3852248